Loading...
•
Sep 30, 2023
EyePoint Pharmaceuticals Q3 2023 Earnings Report
Reported financial results for the third quarter ended September 30, 2023 and highlighted recent corporate developments.
Key Takeaways
EyePoint Pharmaceuticals reported total net revenue of $15.2 million for the third quarter ended September 30, 2023, compared to $10.0 million for the same period in 2022. The net loss was $12.6 million, or ($0.33) per share, compared to a net loss of $18.4 million, or ($.49) per share, for the prior year period.
Positive masked safety data update for EYP-1901 in ongoing PAVIA and DAVIO 2 Phase 2 clinical trials as of October 1, 2023 with no drug related ocular or systemic SAEs reported.
Leadership strengthened with the appointment of Stuart Duty to the Board of Directors and the promotion of George Elston to Executive Vice President.
Topline data for Phase 2 DAVIO 2 trial anticipated in December 2023 and Phase 2 PAVIA trial in 2Q 2024.
Management to host a conference call and webcast today at 8:30 a.m. ET.
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals Revenue by Segment
Revenue by Segment
Product sales, net Revenue
CapyFin.comLicense and royalties Revenue
CapyFin.com Forward Guidance
We expect the cash, cash equivalents and investments on September 30, 2023 will enable us to fund our current and planned operations into 2025.
Revenue & Expenses
Visualization of income flow from segment revenue to net income